Navigation Links
OncoSec Medical to Present at Noble Financial Capital Markets' Ninth Annual Equity Conference on January 22
Date:1/17/2013

ermato-Oncology (EADO)

The EADO is a non-profit organization funded in 1999 to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical and experimental research. For more information: www.eado.org

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking s
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 4, 2015 BioElectronics Corporation (OTC Pink: ... Pain Therapy medical devices, announced today that its ... 7-day trial device has been published in the ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic ... an assessment.  Chronic pain is ...
(Date:8/4/2015)... 2015 Second Quarter 2015 Highlights: ... second quarter of 2014 , Net earnings attributable to ... million after adjustments , Diluted net earnings per share ... increased 15.2% to $99.4 million 2015 Outlook: ... range of 24.0% to 26.0%; Adjusted EBITDA margin remains between ...
(Date:8/4/2015)... Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ) today reported ... June 30, 2015 and updated its financial guidance for ... this morning, August 4, 2015, at 10:30 AM ET. ... by dialing (855) 582-8078. The conference ID is 90889796. ... revenues of $38.3 million, an increase of 118% as compared ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 3Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 4Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 6Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 7Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 8Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 9Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 10Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 11Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 12Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 13Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 14Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 15Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 16Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 17Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 18Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 19Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 20Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 21Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 22Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 23Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 24Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 25Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 26Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 27Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 28Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 29Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 30Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 31Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 32Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 33ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3
... First Presentation of Full Data Set from the TRIUMPH-1 Trial of ... ... SPRING, Md., May 21 United,Therapeutics Corporation (Nasdaq: UTHR ) ... seven presentations concerning,the treatment of pulmonary arterial hypertension (PAH) with treprostinil,were ...
... of Four HUMIRA Patients from CHARM Study in Remission at ... ... 21 Results from an,open-label extension study of two Abbott ... treated with,HUMIRA(R) (adalimumab) achieved long-term clinical remission and clinical,response, respectively, ...
Cached Medicine Technology:Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 3Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 4Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 5Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 6Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 2Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 3Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 4Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 5Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 6Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 7
(Date:8/5/2015)... ... August 05, 2015 , ... Available in select spas and at ... quartet of beauty-enhancing marine and plant oils. A perfect complement to Phytomer’s top selling ... out for its lovely scent and soothing properties. Formulated as a light and comfortable ...
(Date:8/5/2015)... ... August 05, 2015 , ... ... SweetLeaf®, was honored as one of this year’s 50 Most Influential Women in ... in Arizona business. Carol May’s long-standing dedication to the well-being of consumers through ...
(Date:8/4/2015)... ... August 04, 2015 , ... NOVA Pride , Northern Virginia’s ... how they love or identify, to join them in paving “The Road Ahead” at ... Events Center on Saturday, October 3, 2015, from 12-9pm. In order to ensure the ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... announces the Assisted Dumbbell Bench Rack, a fitness invention that eliminates the need ... "The Gym, Health and Fitness Clubs industry is worth $30 billion," says Scott ...
(Date:8/4/2015)... ... August 04, 2015 , ... Rhode Island Medical Imaging (RIMI) is pleased ... Medical Building on Wake Robin Road in Lincoln, RI. This satellite office will ... the most extensive out-patient x-ray hours in the state, which includes evenings and weekends. ...
Breaking Medicine News(10 mins):Health News:Phytomer launches ROSÉE SOIN Radiance Replenishing Oil 2Health News:Phytomer launches ROSÉE SOIN Radiance Replenishing Oil 3Health News:Phytomer launches ROSÉE SOIN Radiance Replenishing Oil 4Health News:Carol May Named One of the Most Influential Woman in Arizona 2Health News:Carol May Named One of the Most Influential Woman in Arizona 3Health News:Carol May Named One of the Most Influential Woman in Arizona 4Health News:NOVA Pride Announces Theme for the 2015 Northern Virginia Pride Festival 2Health News:NOVA Pride Announces Theme for the 2015 Northern Virginia Pride Festival 3Health News:NOVA Pride Announces Theme for the 2015 Northern Virginia Pride Festival 4Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 3Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 4Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 5Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 6Health News:Rhode Island Medical Imaging Opens Satellite Imaging Center on Wake Robin Road in Lincoln 2
... Company,(Nasdaq: PRGO ; TASE) today announced that it ... Cream 0.1%, a generic version of,VANOS(R) Cream 0.1%. The ... an,ANDA with a Paragraph IV certification against VANOS(R)., ... to relieve the inflammation and itching caused by certain,skin ...
... suggest current dietary requirements need to be increased , , MONDAY, ... the risk of heart attack in men, says a U.S. ... and Brigham and Women,s Hospital, Boston, analyzed medical records and ... had a nonfatal heart attack or fatal heart disease, and ...
... Francisco, Calif., June 07, 2008 Results from ... announced today at the American Diabetes Association (ADA) ... Development Center, Inc. Alogliptin, which has been ... dipeptidyl peptidase-4 (DPP-4), is currently under investigation as ...
... June 9 The Department of,Labor & Industry invites the ... the 10th annual Health & Safety Day from 10 a.m. ... Wing Rotunda in,Harrisburg., The event will feature an array ... home. Visitors to the event can,receive - free of charge ...
... wheel, with 2.2% reporting accidents as result , , MONDAY, June ... of sleep may be a real problem for American college ... at the University of North Texas found that 17 percent ... that group reported having accidents because of this drowsiness. A ...
... College of Physicians (ACP) today pledged its support for ... Patients and Providers Act of 2008. , "The College ... addresses and incorporates three of our top legislative priorities," ... Max Baucus (D-MT), chairman of the Senate Finance Committee. ...
Cached Medicine News:Health News:Perrigo Confirms Filing for Generic Version of VANOS(R) 2Health News:Phase 3 results for alogliptin 2Health News:Phase 3 results for alogliptin 3Health News:Sleepy Driving Prevalent Among Collegians 2Health News:ACP pledges support for Medicare improvements for Patients and Providers Act of 2008 2
The Vitatron Slimtine S lead series are endocardial leads with an excellent history of reliability and optimal handling en pacing performance....
Bipolar Atrial "J" Lead...
Unipolar temporary atrial pacing lead is smaller and thinner than Medtronics standard temporary pacing leads. It is well suited for thin, delicate, atrial tissue....
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: